{"url_path":"/sec/trvi/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-257365-index.html","accession_number":"0001193125-26-257365","cik":"0001563880","ticker":"TRVI","issuer_name":"Trevi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-257365-index.html","primary_entity_key":"0001563880","primary_entity_name":"Trevi Therapeutics, Inc."},"word_count":165,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders\n\nOn June 3, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company’s stockholders voted on the following proposals:\n\n1. Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders.\n\n \n\nFor:\n\n \n\n \n\n81,567,765\n\n \n\nWithheld:\n\n \n\n \n\n18,635,726\n\n \n\nBroker Non-Votes:\n\n \n\n \n\n14,140,404\n\n \n\n2. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.\n\n \n\nFor:\n\n \n\n \n\n114,001,970\n\n \n\nAgainst:\n\n \n\n \n\n223,323\n\n \n\nAbstain:\n\n \n\n \n\n118,602\n\n \n\n \n\n3. The compensation of the Company's named executive officers was approved, on an advisory basis.\n\n \n\nFor:\n\n \n\n \n\n98,119,461\n\n \n\nAgainst:\n\n \n\n \n\n1,982,126\n\n \n\nAbstain:\n\n \n\n \n\n101,904\n\n \n\nBroker Non-Votes:\n\n \n\n \n\n14,140,404\n\n \n\n \n\n4. The A&R 2019 Plan was approved.\n\n \n\nFor:\n\n \n\n \n\n98,140,470\n\n \n\nAgainst:\n\n \n\n \n\n1,961,030\n\n \n\nAbstain:\n\n \n\n \n\n101,991\n\n \n\nBroker Non-Votes:\n\n \n\n \n\n14,140,404\n\n \n\n \n\n5. The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved.\n\n \n\nFor:\n\n \n\n \n\n110,453,620\n\n \n\nAgainst:\n\n \n\n \n\n3,872,599\n\n \n\nAbstain:\n\n \n\n \n\n17,676"}